David A. Siegel Acorda Therapeutics Inc Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.55 - $1.0 $165 - $300	-300 Reduced 2.0%	14,700 $8,000
Q4 2022 Feb 14, 2023	BUY	$0.52 - $0.77 $104 - $154	200 Added 1.35%	15,000 $11,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.53 $115 - $212	400 Added 2.78%	14,800 $4,000
Q1 2022 May 16, 2022	SELL	$1.61 - $2.5 $4,669 - $7,250	-2,900 Reduced 16.76%	14,400 $23,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $4.71 $12,189 - $24,963	5,300 Added 44.17%	17,300 $41,000
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.79 $40,320 - $57,480	12,000 New	12,000 $55,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.